Oral silodosin on lower urinary tract symptoms due to double-j stent: a prospectively randomized study

Author(s): Chung-Jing Wang, Po-Chao Tsai, Chien-Hsing Chang

Introduction: To evaluate the effect of silodosin in improving symptoms and quality of life in patients with indwelling double-J ureteral stents, using a specific questionnaire. Experiments: One hundred sixty-one patients with symptomatic distal ureteral stones <15 mm diameter were enrolled. In group 1, 78 patients received a placebo (lactose tablet) for two weeks. In group 2, 83 patients received 4 mg of silodosin once daily before bed for two weeks. All patients completed the validated ureteral stent symptomquestionnaire (USSQ) and International Prostate Symptom Scale (IPSS) for quality of life for evaluating the symptoms of double-J stents and quality of life after double- J stent insertion and removal, respectively. Statistical analysis was performed using the chi-square test, Mann-Whitney U test, and Fisher’s exact test, as appropriate. Results: One hundred sixty-one patients completed the study. No significant statistical difference was observed in patient age, gender distribution, body height, stone size, or operative times (p>0.005). The mean urinary symptom index was significantly less (p<0.001) in group 2 patients. Stent-related pain was similar in both groups, but the overall intensity as identified on the visual analog scale was more severe in group 1 patients (p<0.001). General health scores were significantly greater in group 1 patients, leading to significant (p<0.001) interference with their lives related to the presence of the stent. The mean score of IPSS quality of life was 4.18±0.79 in group 1 and 1.57±0.68 in group 2. Conclusion: The administration of silodosin improves stent-related urinary symptoms, pain, and voiding flank pain.

Share this       

Share this Page.

Table of Contents

Scimago Journal Rank

SCImago Journal & Country Rank